Athena Athena

X
[{"orgOrder":0,"company":"Jiangsu Atom Bioscience & Pharmaceutical","sponsor":"Xicheng Jinrui Equity Investment Fund","pharmaFlowCategory":"D","amount":"$45.0 million","upfrontCash":"Undisclosed","newsHeadline":"Atom Bioscience Raises $45 Million in Series C Round of Financing to Advance Development of Small Molecule Drugs for Inflammatory and Metabolic Diseases","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Rheumatology","graph2":"Phase II"},{"orgOrder":0,"company":"Jiangsu Atom Bioscience & Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atom Bioscience Announces Positive Phase 2a Results For Investigational New Drug to Treat Chronic Gout","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Rheumatology","graph2":"Phase II"},{"orgOrder":0,"company":"Jiangsu Atom Bioscience & Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atom Bioscience to Present Final Data from its Positive Phase 2a Clinical Trial in Chronic Gout at American College of Rheumatology Annual Meeting, Nov. 10 \u2013 14, in Philadelphia, PA","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Rheumatology","graph2":"Phase II"},{"orgOrder":0,"company":"Jiangsu Atom Bioscience & Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atom Bioscience Announces Positive Results of Phase 2a China Clinical Trial of Its URAT1 Inhibitor for Chronic Gout","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Rheumatology","graph2":"Phase II"},{"orgOrder":0,"company":"Jiangsu Atom Bioscience & Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atom Bioscience Doses First Patient in Phase 2b\/3 Clinical Trial of a New Treatment for Chronic Gout","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Rheumatology","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"Jiangsu Atom Bioscience & Pharmaceutical","sponsor":"Kaitai Capital","pharmaFlowCategory":"D","amount":"$83.0 million","upfrontCash":"Undisclosed","newsHeadline":"Atom Bioscience Raises $83M in a D-Round Financing to Support Global Pivotal Clinical Trials of ABP-671, a New Treatment for Chronic Gout","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Rheumatology","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"Jiangsu Atom Bioscience & Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atom Bioscience Receives FDA IND Clearance for Clinical Trial of ABP-745 for Acute Gout","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"IND Enabling","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Rheumatology","graph2":"IND Enabling"}]

Find Clinical Drug Pipeline Developments & Deals by Jiangsu Atom Bioscience & Pharmaceutical

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            ABP-745 is an oral small molecule drug which is being evaluated for the treatment of acute gout. Preclinical trials showed that it can significantly reduce levels of inflammatory factors & compared with similar drugs, it has good efficiency & significant safety improvement.

            Lead Product(s): ABP-745

            Therapeutic Area: Rheumatology Product Name: ABP-745

            Highest Development Status: IND Enabling Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 02, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The financing will be used for completion of global pivotal clinical trials of ABP-671, its unique orally administered URAT1 inhibitor for chronic gout and to advance to clinical stage the company’s innovative pipeline of drugs for inflammatory and metabolic diseases.

            Lead Product(s): ABP-671

            Therapeutic Area: Rheumatology Product Name: ABP-671

            Highest Development Status: Phase II/ Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Kaitai Capital

            Deal Size: $83.0 million Upfront Cash: Undisclosed

            Deal Type: Series D Financing October 16, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            ABP-671 is a small molecule inhibitor of the urate transporter 1 (URAT1) protein, which is involved in the reabsorption of uric acid by the kidneys. In gout patients, ABP-671 reduces the reabsorption of uric acid, increasing its excretion in urine.

            Lead Product(s): ABP-671

            Therapeutic Area: Rheumatology Product Name: ABP-671

            Highest Development Status: Phase II/ Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 09, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            ABP-671 is a small molecule inhibitor of the urate transporter 1 (URAT1) protein, which is involved in the reabsorption of uric acid by the kidneys. In gout patients, ABP-671 reduces the reabsorption of uric acid, increasing its excretion in urine.

            Lead Product(s): ABP-671

            Therapeutic Area: Rheumatology Product Name: ABP-671

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 01, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            ABP-671 was well tolerated, with the overall incidence of treatment emergent adverse events similar between the ABP-671 treatment cohorts and the placebo cohorts.

            Lead Product(s): ABP-671

            Therapeutic Area: Rheumatology Product Name: ABP-671

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 10, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Preliminary data suggest Atom’s compound ABP-671, a small molecule inhibitor of the urate transporter (URAT1) protein reduces uric acid levels to prevent gout flare-ups without the adverse side effects of existing treatments.

            Lead Product(s): ABP-671

            Therapeutic Area: Rheumatology Product Name: ABP-671

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 21, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Funding will support company’s anticipated global Phase III clinical trial of lead product, ABP-671, for treatment of hyperuricemia and gout, which affects more than 255 million people worldwide.

            Lead Product(s): ABP-671

            Therapeutic Area: Rheumatology Product Name: ABP-671

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Xicheng Jinrui Equity Investment Fund

            Deal Size: $45.0 million Upfront Cash: Undisclosed

            Deal Type: Series C Financing January 05, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY